147 related articles for article (PubMed ID: 37848674)
1. High pyroptosis activity in pancreatic adenocarcinoma: poor prognosis and oxaliplatin resistance.
Wang G; Chen J; Dai S; Zhang J; Gao Y; Yin L; Jiang K; Miao Y; Lu Z
Apoptosis; 2024 Apr; 29(3-4):344-356. PubMed ID: 37848674
[TBL] [Abstract][Full Text] [Related]
2. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.
Yan C; Niu Y; Li F; Zhao W; Ma L
J Transl Med; 2022 Oct; 20(1):455. PubMed ID: 36199146
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer.
Li S; Yue M; Xu H; Zhang X; Mao T; Quan M; Ma J; Wang Y; Ge W; Wang Y; Xue S; Shentu D; Cui J; Wang L
Cancer Lett; 2023 Jun; 564():216206. PubMed ID: 37120007
[TBL] [Abstract][Full Text] [Related]
4. Pyroptosis-related genes regulate proliferation and invasion of pancreatic cancer and serve as the prognostic signature for modeling patient survival.
Song W; Liu Z; Wang K; Tan K; Zhao A; Li X; Yuan Y; Yang Z
Discov Oncol; 2022 May; 13(1):39. PubMed ID: 35633405
[TBL] [Abstract][Full Text] [Related]
5. Identification of a potential prognostic model combining pyroptosis-related gene with immune microenvironment for pancreatic ductal adenocarcinoma.
Xie H; Xu J; Zhao Q
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17175-17187. PubMed ID: 37782328
[TBL] [Abstract][Full Text] [Related]
6. HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1.
Xia R; Hu C; Ye Y; Zhang X; Li T; He R; Zheng S; Wen X; Chen R
Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36825600
[TBL] [Abstract][Full Text] [Related]
7. The Pyroptosis-Related Signature Composed of GSDMC Predicts Prognosis and Contributes to Growth and Metastasis of Hepatocellular Carcinoma.
Li M; Jiang Q; Liu X; Han L; Chen S; Xue R
Front Biosci (Landmark Ed); 2023 Oct; 28(10):235. PubMed ID: 37919059
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
9. Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer.
Zheng S; Tian Q; Yuan Y; Sun S; Li T; Xia R; He R; Luo Y; Lin Q; Fu Z; Zhou Y; Chen R; Hu C
J Exp Clin Cancer Res; 2023 Nov; 42(1):324. PubMed ID: 38012734
[TBL] [Abstract][Full Text] [Related]
10. Pyroptosis regulators exert crucial functions in prognosis, progression and immune microenvironment of pancreatic adenocarcinoma: a bioinformatic and in vitro research.
Bai Z; Xu F; Feng X; Wu Y; Lv J; Shi Y; Pei H
Bioengineered; 2022 Jan; 13(1):1717-1735. PubMed ID: 35000541
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer.
Wang Z; Qin J; Zhao J; Li J; Li D; Popp M; Popp F; Alakus H; Kong B; Dong Q; Nelson PJ; Zhao Y; Bruns CJ
Theranostics; 2020; 10(16):7178-7192. PubMed ID: 32641986
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
[TBL] [Abstract][Full Text] [Related]
13. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
Okada Y; Takahashi N; Takayama T; Goel A
Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
[TBL] [Abstract][Full Text] [Related]
14. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair.
Zhang X; Zheng S; Hu C; Li G; Lin H; Xia R; Ye Y; He R; Li Z; Lin Q; Chen R; Zhou Q
Oncogene; 2022 Apr; 41(16):2372-2389. PubMed ID: 35264742
[TBL] [Abstract][Full Text] [Related]
16. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway.
Zheng S; Hu C; Lin H; Li G; Xia R; Zhang X; Su D; Li Z; Zhou Q; Chen R
J Exp Clin Cancer Res; 2022 Feb; 41(1):71. PubMed ID: 35189958
[TBL] [Abstract][Full Text] [Related]
17. A potential prognostic marker and therapeutic target: SPOCK1 promotes the proliferation, metastasis, and apoptosis of pancreatic ductal adenocarcinoma cells.
Li J; Ke J; Fang J; Chen JP
J Cell Biochem; 2020 Jan; 121(1):743-754. PubMed ID: 31478239
[TBL] [Abstract][Full Text] [Related]
18. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
Zhang L; Yao J; Li W; Zhang C
Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
[TBL] [Abstract][Full Text] [Related]
19. MST1 Suppresses Pancreatic Cancer Progression via ROS-Induced Pyroptosis.
Cui J; Zhou Z; Yang H; Jiao F; Li N; Gao Y; Wang L; Chen J; Quan M
Mol Cancer Res; 2019 Jun; 17(6):1316-1325. PubMed ID: 30796177
[TBL] [Abstract][Full Text] [Related]
20. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
